Impact of residual 18F-fluoride in 18F-FDOPA for the diagnosis of neuroblastoma

详细信息    查看全文

• 作者：Ya-Yao Huang ; Kai-Yuan Tzen ; Yen-Lin Liu ; Ching-Hong Chiu…
• 关键词：18F ; FDOPA PET ; 18F ; Fluoride ; Neuroblastoma ; Metastasis
• 刊名：Annals of Nuclear Medicine
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：29
• 期：6
• 页码：489-498
• 全文大小：1,864 KB
• 参考文献：1.Mueller W, Coppenrath E, Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol. 2012;43(4):418-7.PubMed View Article
  2.Ara T, DeClerck YA. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev. 2006;25(4):645-7.PubMed View Article
  3.DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol/Oncol. 1999;21(3):181-.View Article
  4.Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55(1):97-20.PubMed View Article
  5.Kushner B. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45(7):1172-8.PubMed
  6.Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54:1-.View Article
  7.Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39(1):57-1.PubMed View Article
  8.Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med. 2012;37(4):e73-.PubMed View Article
  9.Rufini V, Treglia G, Montravers F, Giordano A. Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis. Clin Transl Imaging. 2013;1(2):1-2.View Article
  10.Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang S-C. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48(10):1651-1.PubMed View Article
  11.Piccardo A, Puntoni M, Lopci E, Conte M, Foppiani L, Sorrentino S, et al. Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014;41(6):1046-6.PubMed View Article
  12.Howman-Giles R, London K. Paediatric bone scintigraphy: bone metastases. In: Fogelman I, Gnanasegaran G, Van der Wall H, editors. Radionuclide and hybrid bone imaging. Berlin: Springer; 2012. p. 855-7.View Article
  13.Howman-Giles R, Shaw P, Uren R, Chung D. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37(4):286-02.PubMed View Article
  14.Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-l -18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49(4):573-6.PubMed View Article
  15.Kao CHK, Hsu WL, Xie HL, Lin MC, Lan WC, Chao HY. GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP “Fluorodopa F18 Injection- Ann Nucl Med. 2011;25(5):309-6.PubMed View Article
  16.USP36/NF31. Fluorodopa F18 Injection.? The United States Pharmacopeia, 36th ed., and The National Formulary, 31th ed. 36 ed. Rockville, M.D.: United States Pharmacopeial Convention, Inc.; 2013. p. 2193-.
  17.Füchtner F, Angelberger P, Kvaternik H, Hammerschmidt F, Simovc BP, Steinbach J. Aspects of 6-[18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity. Nucl Med Biol. 2002;29(4):477-1.PubMed View Article
  18.Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-7.PubMed
  19.Tsai H, Hsi B, Hung I, Yang C, Lin J, Chen J, et al. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Hum Pathol. 2004;35(11):1397-03.PubMed View Article
  20.Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313-3.PubMed Central PubMed View Article
  21.Kreissman S, Seeger R, Matthay K, London W, Sposto R, Grupp S, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999-008.PubMed Central PubMed View Article
  22.Chang H, Lee H, Hu M, Tsao P, Juan H, Huang M, et al. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res. 2010;16(17):4411-0.PubMed View Article
  23.Hsu W, Jen Y, Lee H, Kuo M, Tsao P, Chen C, et al. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Ann Surg Oncol. 2006;13(2):238-4.PubMed View Article
  24.Luxen A, Guillaume M, Melega W, Pike V, Solin O, Wagner R. Production of 6-[18F] fluoro-l-DOPA and its metabolism in vivo—a critical review. Int J Rad Appl Instrum B. 1992;19(2):149-8.PubMed
• 作者单位：Ya-Yao Huang (1)
  Kai-Yuan Tzen (1) (2)
  Yen-Lin Liu (3) (4)
  Ching-Hong Chiu (1)
  Chia-Ling Tsai (1)
  Hsiang-Ping Wen (1)
  Kuang-Hua Tang (1)
  Chien-Chu Liu (1)
  Chyng-Yann Shiue (1) (2) (5)
  
  1. PET Center, Department of Nuclear Medicine, National Taiwan University Hospital, 7 Chung-Shan S. Rd., Taipei, 100, Taiwan
  2. Molecular Imaging Center, National Taiwan University, No. 81, Changxing St., Taipei, 106, Taiwan
  3. Department of Pediatrics, Taipei Medical University Hospital, 252 Wuxing St., Xinyi District, Taipei, 110, Taiwan
  4. PhD of Translational Medicine Program, National Taiwan University and Academia Sinica, 1 Jen Ai Rd. Sec. 1, Taipei, 100, Taiwan
  5. PET Center, Department of Nuclear Medicine, Tri-Service General Hospital, 325 Sec. 2, Cheng-Kung Rd., Taipei, 114, Taiwan
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology;
• 出版者：Springer Japan
• ISSN：1864-6433

文摘

Objective PET imaging with 18F-FDOPA has been successfully applied in the diagnosis and surveillance of neuroblastoma (NB) by targeting the overexpression of aromatic l-amino acid decarboxylase. This study aims to assess the impact of residual 18F-fluoride on 18F-FDOPA PET in NB and to implement a method to maintain low 18F-fluoride content in future studies. Methods Automatic synthesis of 18F-FDOPA was based on the electrophilic method using TRACERlab FXFE module. Radio-TLC was employed to determine residual 18F-fluoride levels. We analyzed the impact of residual 18F-fluoride on the images of 35 patients undergoing 18F-FDOPA PET at initial diagnosis and/or follow-ups of NB. Results In 35 batches of 18F-FDOPA products from 9/28/2010 to 07/27/2011, the mean residual 18F-fluoride level was 4.4?% (range 0.2-9.1?%). Residual 18F-fluoride level ?.0?% was associated with dense uptake in the growth plates, skull, and pelvis on PET scans, which may interfere with the interpretation of 18F-FDOPA imaging in NB. By applying stringent restraints in 18F-FDOPA?production, including regular renewal of reagents, exclusive use? of NH4OH, and timely replacement of HPLC column, the incidence of 18F-FDOPA batches with residual 18F-fluoride level ?.0?% was reduced from 33 to 4?% (P?<?0.0001) during 7/30/2011-/29/2013. Conclusion By monitoring residual 18F-fluoride levels and keeping stringent restraint procedures, low 18F-fluoride content was achieved in most batches of 18F-FDOPA, which diminished false-positive skeletal uptake. An appropriate upper limit of 18F-fluoride level is suggested to be included in the criteria of routine quality control of 18F-FDOPA productions.